carbon monoxide has been researched along with Schizophrenia in 18 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty smokers with schizophrenia were recruited and randomized to receive either varenicline or placebo." | 9.22 | Adjunctive varenicline treatment for smoking reduction in patients with schizophrenia: A randomized double-blind placebo-controlled trial. ( Jeon, DW; Jung, DU; Kim, SJ; Kong, BG; Moon, JJ; Oh, MK; Seo, YS; Shim, JC, 2016) |
| "This proof-of-concept study investigated the feasibility and initial efficacy of combining a contingency management intervention with bupropion to reduce smoking in people with schizophrenia." | 9.15 | Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. ( Kaplan, GB; Reid, N; Rohsenow, DJ; Swift, RM; Tidey, JW, 2011) |
| "The objective of this study was to examine whether there is a benefit of adding bupropion SR to high-dose combination nicotine replacement therapy (NRT) and weekly group cognitive behavioral therapy (CBT) for smoking reduction or cessation in schizophrenia." | 9.12 | A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. ( Birnbaum, A; Cather, C; Culhane, MA; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Horowitz, J; Hsieh, E; Rigotti, NA; Schoenfeld, DA, 2007) |
| "The purpose of this study was to determine the effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia." | 9.11 | The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. ( Chen, R; Chou, KR; Ku, CH; Lee, JF; Lu, RB, 2004) |
| "This study was conducted to examine the effects of contingent monetary reinforcement (CM) for smoking reduction, with and without transdermal nicotine, on cigarette smoking in individuals with schizophrenia." | 9.10 | Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. ( Higgins, ST; O'Neill, SC; Tidey, JW, 2002) |
| " Expired carbon monoxide (CO) and serum nicotine and cotinine were measured in 89 smokers with schizophrenia and 53 control smokers immediately after smoking an afternoon cigarette." | 7.74 | Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia. ( Benowitz, NL; Foulds, J; Gandhi, KK; Steinberg, ML; Williams, JM; Ziedonis, DM, 2007) |
| "Ten patients with schizophrenia participated in 120-min free-smoking sessions when actively psychotic and free of antipsychotic medications, and again after the initiation of haloperidol treatment." | 7.69 | Haloperidol increases smoking in patients with schizophrenia. ( Freudenreich, O; Levin, ED; McEvoy, JP; Rose, JE, 1995) |
| "Sixty smokers with schizophrenia were recruited and randomized to receive either varenicline or placebo." | 5.22 | Adjunctive varenicline treatment for smoking reduction in patients with schizophrenia: A randomized double-blind placebo-controlled trial. ( Jeon, DW; Jung, DU; Kim, SJ; Kong, BG; Moon, JJ; Oh, MK; Seo, YS; Shim, JC, 2016) |
| "This proof-of-concept study investigated the feasibility and initial efficacy of combining a contingency management intervention with bupropion to reduce smoking in people with schizophrenia." | 5.15 | Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. ( Kaplan, GB; Reid, N; Rohsenow, DJ; Swift, RM; Tidey, JW, 2011) |
| "The objective of this study was to examine whether there is a benefit of adding bupropion SR to high-dose combination nicotine replacement therapy (NRT) and weekly group cognitive behavioral therapy (CBT) for smoking reduction or cessation in schizophrenia." | 5.12 | A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. ( Birnbaum, A; Cather, C; Culhane, MA; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Horowitz, J; Hsieh, E; Rigotti, NA; Schoenfeld, DA, 2007) |
| "The purpose of this study was to determine the effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia." | 5.11 | The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. ( Chen, R; Chou, KR; Ku, CH; Lee, JF; Lu, RB, 2004) |
| "This study was conducted to examine the effects of contingent monetary reinforcement (CM) for smoking reduction, with and without transdermal nicotine, on cigarette smoking in individuals with schizophrenia." | 5.10 | Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia. ( Higgins, ST; O'Neill, SC; Tidey, JW, 2002) |
| " Expired carbon monoxide (CO) and serum nicotine and cotinine were measured in 89 smokers with schizophrenia and 53 control smokers immediately after smoking an afternoon cigarette." | 3.74 | Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia. ( Benowitz, NL; Foulds, J; Gandhi, KK; Steinberg, ML; Williams, JM; Ziedonis, DM, 2007) |
| "Ten patients with schizophrenia participated in 120-min free-smoking sessions when actively psychotic and free of antipsychotic medications, and again after the initiation of haloperidol treatment." | 3.69 | Haloperidol increases smoking in patients with schizophrenia. ( Freudenreich, O; Levin, ED; McEvoy, JP; Rose, JE, 1995) |
| "Smoking cessation is possible for individuals with schizophrenia but the relapse rate is high." | 1.39 | Counseling and exercise intervention for smoking reduction in patients with schizophrenia: a feasibility study. ( Bernard, PP; Carayol, MS; Dandonneau, L; Esseul, EC; Ninot, GJ; Raymond, L; Xambo, JJ, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarramea Crespo, F | 1 |
| Jaén-Moreno, MJ | 1 |
| Gutiérrez-Rojas, L | 1 |
| Balanzá-Martínez, V | 1 |
| García-Alvarez, L | 1 |
| Saiz Martínez, PA | 1 |
| Garcia-Portilla, MP | 1 |
| Guler, I | 1 |
| Bobes, J | 1 |
| Galati, S | 1 |
| Städler, C | 1 |
| Brunette, MF | 1 |
| Ferron, JC | 1 |
| Drake, RE | 1 |
| Devitt, TS | 1 |
| Geiger, PT | 1 |
| McHugo, GJ | 1 |
| Jonikas, JA | 1 |
| Cook, JA | 1 |
| Jeon, DW | 1 |
| Shim, JC | 1 |
| Kong, BG | 1 |
| Moon, JJ | 1 |
| Seo, YS | 1 |
| Kim, SJ | 1 |
| Oh, MK | 1 |
| Jung, DU | 1 |
| Kelly, DL | 1 |
| McMahon, RP | 1 |
| Weiner, E | 1 |
| Boggs, DL | 1 |
| Dickinson, D | 1 |
| Conley, RR | 1 |
| Buchanan, RW | 2 |
| Tidey, JW | 3 |
| Rohsenow, DJ | 2 |
| Kaplan, GB | 2 |
| Swift, RM | 2 |
| Adolfo, AB | 1 |
| Mann-Wrobel, MC | 1 |
| Bennett, ME | 1 |
| Weiner, EE | 1 |
| Ball, MP | 1 |
| Reid, N | 1 |
| Williams, JM | 2 |
| Gandhi, KK | 2 |
| Lu, SE | 1 |
| Steinberg, ML | 2 |
| Benowitz, NL | 2 |
| Bernard, PP | 1 |
| Esseul, EC | 1 |
| Raymond, L | 1 |
| Dandonneau, L | 1 |
| Xambo, JJ | 1 |
| Carayol, MS | 1 |
| Ninot, GJ | 1 |
| Caponnetto, P | 1 |
| Auditore, R | 1 |
| Russo, C | 1 |
| Cappello, GC | 1 |
| Polosa, R | 1 |
| O'Neill, SC | 1 |
| Higgins, ST | 1 |
| Pedersen, CB | 1 |
| Raaschou-Nielsen, O | 1 |
| Hertel, O | 1 |
| Mortensen, PB | 1 |
| Chou, KR | 1 |
| Chen, R | 1 |
| Lee, JF | 1 |
| Ku, CH | 1 |
| Lu, RB | 1 |
| Smith, RC | 1 |
| Warner-Cohen, J | 1 |
| Matute, M | 1 |
| Butler, E | 1 |
| Kelly, E | 1 |
| Vaidhyanathaswamy, S | 1 |
| Khan, A | 1 |
| Evins, AE | 1 |
| Cather, C | 1 |
| Culhane, MA | 1 |
| Birnbaum, A | 1 |
| Horowitz, J | 1 |
| Hsieh, E | 1 |
| Freudenreich, O | 2 |
| Henderson, DC | 1 |
| Schoenfeld, DA | 1 |
| Rigotti, NA | 1 |
| Goff, DC | 1 |
| Foulds, J | 1 |
| Ziedonis, DM | 1 |
| McEvoy, JP | 1 |
| Levin, ED | 1 |
| Rose, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial[NCT00523445] | Phase 3 | 120 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| Incentives Plus Bupropion for Smoking in Schizophrenics[NCT00136760] | Phase 2 | 57 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Nicotine and Smoking Cessation in Schizophrenia[NCT00307203] | Phase 4 | 51 participants (Actual) | Interventional | 1998-08-31 | Completed | ||
| Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence[NCT00749658] | Phase 2/Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder[NCT00135772] | 100 participants | Observational | 2003-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00136760)
Timeframe: 3 weeks
| Intervention | cigarettes per day (Mean) |
|---|---|
| CM + BUP | 12.7 |
| CM + PLA | 13.9 |
| NR + BUP | 18.8 |
| NR + PLA | 21.0 |
Urinary Cotinine levels at Week 4 (average of last 3 study visits) (NCT00136760)
Timeframe: 3 weeks
| Intervention | ng/ml (Mean) |
|---|---|
| CM + BUP | 755 |
| CM + PLA | 1102 |
| NR + BUP | 1534 |
| NR + PLA | 1408 |
11 trials available for carbon monoxide and Schizophrenia
| Article | Year |
|---|---|
Carbon monoxide feedback in a motivational decision support system for nicotine dependence among smokers with severe mental illnesses.
Topics: Adult; Behavior Therapy; Carbon Monoxide; Decision Support Techniques; Feedback; Female; Humans; Mal | 2013 |
Adjunctive varenicline treatment for smoking reduction in patients with schizophrenia: A randomized double-blind placebo-controlled trial.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Carbon Monoxide; Double-Blind Method; Female; Hum | 2016 |
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
Topics: Adult; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Breath Tests; Carbon Monoxide; | 2008 |
Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program.
Topics: Adult; Carbon Monoxide; Double-Blind Method; Female; Humans; Male; Middle Aged; Motivation; Psychiat | 2011 |
Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia.
Topics: Adult; Behavior Therapy; Behavior, Addictive; Breath Tests; Bupropion; Carbon Monoxide; Combined Mod | 2011 |
Rapid smoking may not be aversive in schizophrenia.
Topics: Adult; Carbon Monoxide; Cotinine; Female; Humans; Male; Middle Aged; Schizophrenia; Schizophrenic Ps | 2013 |
Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study.
Topics: Adult; Carbon Monoxide; Female; Humans; Male; Middle Aged; Prospective Studies; Schizophrenia; Smoki | 2013 |
Contingent monetary reinforcement of smoking reductions, with and without transdermal nicotine, in outpatients with schizophrenia.
Topics: Administration, Cutaneous; Adult; Breath Tests; Carbon Monoxide; Cotinine; Female; Humans; Male; Mot | 2002 |
The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Female; Ganglionic Stimulants; Humans; Longitudin | 2004 |
Effects of nicotine nasal spray on cognitive function in schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Blood Pressure; Carbon Monoxide; Cognition; Cotinine; Double | 2006 |
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Carbon Monoxide; Delayed-Action Preparat | 2007 |
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Carbon Monoxide; Delayed-Action Preparat | 2007 |
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Carbon Monoxide; Delayed-Action Preparat | 2007 |
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Carbon Monoxide; Delayed-Action Preparat | 2007 |
7 other studies available for carbon monoxide and Schizophrenia
| Article | Year |
|---|---|
"Readiness to Change" Predicts Efficacy of Reduction among Smokers with Severe Mental Illness.
Topics: Adult; Bipolar Disorder; Carbon Monoxide; Female; Humans; Longitudinal Studies; Male; Middle Aged; M | 2019 |
Schizophrenia symptoms relieved by CO-induced pallidal lesion: a case report.
Topics: Antipsychotic Agents; Carbon Monoxide; Female; Globus Pallidus; Humans; Magnetic Resonance Imaging; | 2013 |
Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls.
Topics: Administration, Cutaneous; Adult; Carbon Monoxide; Cues; Female; Humans; Male; Nicotine; Schizophren | 2008 |
Counseling and exercise intervention for smoking reduction in patients with schizophrenia: a feasibility study.
Topics: Adult; Carbon Monoxide; Counseling; Exercise; Feasibility Studies; Female; Humans; Male; Middle Aged | 2013 |
Air pollution from traffic and schizophrenia risk.
Topics: Adolescent; Adult; Air Pollutants; Air Pollution, Indoor; Benzene; Carbon Monoxide; Causality; Child | 2004 |
Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia.
Topics: Adult; Analysis of Variance; Carbon Monoxide; Cotinine; Female; Flavoring Agents; Humans; Male; Ment | 2007 |
Haloperidol increases smoking in patients with schizophrenia.
Topics: Adult; Carbon Monoxide; Female; Haloperidol; Humans; Male; Middle Aged; Nicotine; Schizophrenia; Smo | 1995 |